Back to Search Start Over

The effect of TFAP2A/ANXA8 axis on ferroptosis of cervical squamous cell carcinoma (CESC) in vitro.

Authors :
Sheng, Yuehua
Ding, Huiqing
Zhou, Jiaqing
Wu, Yuejing
Xu, Kejun
Yang, Fan
Du, Yongming
Source :
Cytotechnology; Aug2024, Vol. 76 Issue 4, p403-414, 12p
Publication Year :
2024

Abstract

Potential role and associated mechanisms of Annexin A8 (ANXA8), a member of the Annexins family, in cervical squamous cell carcinoma (CESC) are still unclear, despite being upregulated in various malignant tumors. Here, we observed a notably elevated expression of ANXA8 in CESC cells. The inhibition of ANXA8 amplified the susceptibility of CESC cells to Erastin and sorafenib-induced ferroptosis, whereas it exerted minimal influence on DPI7 and DPI10-induced ferroptosis. The results from the Fe<superscript>2+</superscript> concentration assay showed no significant correlation between ANXA8 gene knockdown and intracellular Fe<superscript>2+</superscript> concentration induced by ferroptosis inducers. Western blot analysis demonstrated that the knockdown of ANXA8 did not alter ACSL4 and LPCAT levels under ferroptosis-inducing conditions, but it did result in a reduction in intracellular GSH levels induced by the ferroptosis inducer. Subsequently, we identified TFAP2A as an upstream transcription factor of ANXA8, which plays a role in regulating cell ferroptosis. The knockdown of TFAP2A significantly elevated MDA levels and depressed GSH levels in the presence of a ferroptosis inducer, thereby inhibiting cell ferroptosis. However, this inhibitory effect could be reversed by ANXA8 overexpression. Therefore, our research suggests that the TFAP2A/ANXA8 axis exerts regulatory control over ferroptosis in CESC cells by mediating GSH synthesis in System Xc. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
09209069
Volume :
76
Issue :
4
Database :
Complementary Index
Journal :
Cytotechnology
Publication Type :
Academic Journal
Accession number :
178047655
Full Text :
https://doi.org/10.1007/s10616-024-00619-0